Select Page

Abstract Number: 494 – Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Presenter: Elena Zamagni, MDSession: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMADate & Time: Sunday, December 8, 2024 9:45 AM–10:00 AMLocation: Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)Keywords: Teclistamab, MajesTEC-4,...

Abstract Number: 487 – Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

Presenter: Luca Bertamini, MDSession: 653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical PracticeDate & Time: Sunday, December 8, 2024 9:30 AM–9:45 AMLocation: Pacific Ballroom...